RE:RE:RE:Curious on valuationTRIP is a joke. Run by a guy who used to be a complete idiot on a morning radio show in Toronto with Russell Peters as Chief Creative Officer. They are purely a recreational play, which is a longgggg ways away in the big markets, has no barriers to entry and will be a race to the bottom on prices/margins, much like the cannabis sector.
For me, the only ones worthwhile at this point to invest in and hold for a few years are MindMed, Atai (expected to IPO in the near future) and Compass. All of which have raised the most money. MindMed and Atai have robust pipelines and have a significant amount of cash on hand to help push through trials or make acquisitions. Compass is closest to commercialization, but only has one drug in the pipe, which if successful could be a blockbuster drug.
The other one that intrigues me is Field Trip, which is working hard to solve the supply side for therapists to deliver these therapeutics.
There's plenty of articles/materials out there that you can get from a simple google search to do some research.
skelterhelter wrote: thank you
RiskyBiz928 wrote: Skelter: Try TRIP - also in the shroom space. Cheaper entry, same risk. Market is speculative, boom or bust.